RxDoctor Payments Data

Jeffery Trail, MD

Family Medicine · Spokane, WANPI 1578542486

Payments from drug & device makers

$12,155in general payments, 2019–2025

Across 784 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$946
  • Amgen$903
  • Lilly USA, LLC$629
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$12,01299%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$1,792
AstraZeneca61$1,359
Novo Nordisk99$1,190
Pfizer88$946
Amgen49$903
Lilly USA, LLC35$629
Johnson & Johnson34$597
Kowa Pharmaceuticals America, Inc.65$400
GSK28$324
Exact Sciences14$313
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$307
Boehringer Ingelheim17$286
Sanofi-aventis U.S. LLC18$280
Corcept Therapeutics8$180
Sumitomo Pharma America, Inc.8$179
Otsuka America Pharmaceutical, Inc.8$158
Biohaven Pharmaceuticals, Inc.9$158
Teva Pharmaceuticals USA, Inc.7$151
Lundbeck LLC7$149
Takeda Pharmaceuticals U.S.A., Inc.9$146
E.r. Squibb & Sons, L.L.C.7$136
Novartis7$130
Phathom Pharmaceuticals, Inc.8$92
Astellas Pharma US Inc5$88
Dexcom, Inc.3$85
Alnylam Pharmaceuticals Inc.3$73
Eisai Inc.4$69
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$68
Medtronic(2 entities)3$67
Biohaven Pharmaceutical Holding Company Ltd.3$66
Radius Health, Inc.4$65
Bayer4$64
Antares Pharma, Inc.4$64
Abbott3$51
Corium, LLC2$49
Almatica Pharma LLC2$42
Hologic Sales And Service, LLC2$41
Merck3$41
Boston Scientific1$33
Globus Medical1$32
Edwards Lifesciences1$26
Medicomp Inc1$24
Mylan Specialty L.p.1$24
Si-bone, Inc.1$23
Nestle Healthcare Nutrition Inc.1$22
Recordati_rare_diseases_inc.1$21
Xeris Pharmaceuticals, Inc.1$19
Nevro Corp.1$18
Sanofi1$18
Daiichi Sankyo Inc.1$17
Vanda Pharmaceuticals Inc.1$17
Upsher-smith Laboratories LLC1$16
Ironwood Pharmaceuticals, Inc1$16
Apria Healthcare LLC1$15
Collegium Pharmaceutical, Inc.1$15
Sanofi Pasteur Inc.1$14
Grifols USA, LLC1$14
Shire North American Group Inc1$14
Idorsia Pharmaceuticals US Inc1$13

How this compares

$12,155 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$143,312
Medicare patients
348
Services billed
1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$87,486
XareltoRivaroxaban68$80,703
OzempicSemaglutide74$75,130
MounjaroTirzepatide52$64,808
JardianceEmpagliflozin39$52,573
TrulicityDulaglutide29$32,133
VraylarCariprazine Hcl18$25,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$24,325
JanuviaSitagliptin Phosphate14$18,406
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$13,079
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen422$12,748
ZenpepLipase/Protease/Amylase11$12,421
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$11,855
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$9,025
Omeprazole371$8,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$629$96,94181 claims
PfizerEliquis$946$87,48671 claims
Johnson & JohnsonXarelto$597$80,70368 claims
Novo NordiskOzempic$1,190$75,13074 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$286$67,60366 claims
GSKTrelegy Ellipta, Arnuity Ellipta$324$29,53551 claims
AbbVieVraylar, Synthroid$1,792$28,38282 claims
MerckJanuvia$41$18,40614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →